FOXM1 and breast cancer: To establish further the physiological and clinical relevance of the negative regulation of FOXM1 expression by RNF168 in breast cancer, FOXM1 and RNF168 expression was assessed by immunohistochemistry in 116 breast cancer patient samples (Figure 12).